Q-omics provides the consensus-scored GAN profile across patient tissues and cancer cell-line models. GAN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GAN is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, GAN RNA expression shows 21,639 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRP as cancer lineages where GAN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAN survival associations across molecular data types. GAN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAN RNA expression–survival associations across cancer types. High GAN expression shows unfavorable associations in ACC, LIHC, BLCA and MESO, but favorable associations in SCLC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GAN RNA expression.
This table summarizes GAN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GAN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAN shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRP, KIRC, LUSC and LIHC. The KIRP box plot shows higher GAN RNA expression in tumor versus normal tissue (log2 FC = +0.585, t-test p < 0.001).
This table shows molecular features associated with GAN in patient tissues and cancer cell lines. In patient samples, GAN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GAN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
